ImmunoPET imaging for detecting malignant cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on optimizing a new imaging technique called CD70-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) to evaluate its effectiveness in diagnosing malignant cancers such as renal cancer, lymphoma, and nasopharyngeal carcinoma. Patients with confirmed or suspected malignancies will undergo whole-body scans after receiving a tracer injection, and the imaging results will be quantitatively analyzed. The study aims to compare the diagnostic efficacy of this new imaging method against conventional imaging techniques.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18-80 year-old and of either sex；
* Histologically confirmed diagnosis of renal cancer (especially ccRCC)/lymphoma/NPC or suspected renal cancer/lymphoma/NPC by diagnostic imaging;
* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.

Exclusion Criteria:

* Pregnancy；
* Severe hepatic and renal insufficiency;
* Allergic to single-domain antibody radiopharmaceuticals.

Where it's running

• Renji Hospital, School of Medicine, Shanghai Jiao Tong University
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Weijun Wei, Ph.D. & M.D. — Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
• Study coordinator: Weijun Wei, Ph.D. & M.D.
• Email: wwei@shsmu.edu.cn
• Phone: 15000083153

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hematopoietic stem cell transplant for blood cancers

  This study is testing two different ways of doing stem cell transplants for people with blood cancers to see which method works better and is safer.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03314974

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Odronextamab for previously untreated low-tumor-volume advanced follicular lymphoma

  This study will try odronextamab, an antibody immunotherapy, in adults with previously untreated low-tumor-volume advanced follicular lymphoma to see if it is safe and effective.

  Recruiting Phase 2 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07128641

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

• Bendamustine–Rituximab–Cytarabine plus Zanubrutinib induction followed by zanubrutinib/rituximab with or without sonrotoclax maintenance for newly diagnosed mantle cell lymphoma

  This trial tests whether giving zanubrutinib with a bendamustine‑rituximab‑cytarabine induction and then continuing zanubrutinib with rituximab, with or without sonrotoclax, helps people with newly diagnosed mantle cell lymphoma stay in remission longer.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Phoenix, Arizona and 6 other locations · NCT06854003

• Treatment for patients with relapsed follicular lymphoma using Axicabtagene Ciloleucel Injection

  This study is testing a new treatment called Axicabtagene Ciloleucel Injection to see if it can help Chinese patients with relapsed follicular lymphoma who have already tried other therapies.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06826118

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.